keyword
MENU ▼
Read by QxMD icon Read
search

Cancer associated thrombosis

keyword
https://www.readbyqxmd.com/read/29775552/right-colon-resection-for-colon-cancer-does-surgical-approach-matter
#1
Ivy N Haskins, Tammy Ju, Matthew Skancke, Xiangyu Kuang, Richard L Amdur, Fred Brody, Vincent Obias, Samir Agarwal
BACKGROUND: Surgical resection with curative intent remains the standard of care for colon cancer. This study aims to compare the 30-day outcomes and oncologic results following open, laparoscopic, and robot-assisted right colon resection for colon cancer using the Targeted Colectomy American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. MATERIALS AND METHODS: All patients undergoing elective, right colon resection with primary anastomosis were identified within the targeted colectomy ACS-NSQIP database...
May 18, 2018: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/29775482/risk-of-venous-thromboembolism-in-association-with-factor-v-leiden-in-cancer-patients-the-edith-case-control-study
#2
Adeline Heraudeau, Aurélien Delluc, Mickaël Le Henaff, Karine Lacut, Christophe Leroyer, Benoit Desrues, Francis Couturaud, Cécile Tromeur
BACKGROUND: Cancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation. The impact of the factor V Leiden on the risk of VTE in cancer patients remains uncertain. OBJECTIVE: To assess the impact of factor V Leiden mutation in cancer-associated thrombosis. METHODS: The EDITH hospital-based case-control study enrolled 182 patients with cancer and VTE as well as 182 control patients with cancer, matched for gender, age and cancer location, between 2000 and 2012, in the University Hospital of Brest...
2018: PloS One
https://www.readbyqxmd.com/read/29771187/advanced-stage-breast-cancer-is-associated-with-catheter-tip-thrombus-formation-following-implantable-central-venous-port-placement
#3
Mina S Makary, Alexander Lionberg, Mamdouh Khayat, Maryam B Lustberg, Jamal AlTaani, Xueliang J Pan, Richard R Layman, Subha V Raman, Rachel M Layman, Joshua D Dowell
Purpose Catheter-tip associated thrombosis is not uncommon in patients with implantable central venous ports; however, the prevalence and clinical impact of this complication on patient management is unclear. This study aims to identify risk factors for thrombus formation in a large population receiving serial echocardiograms (echo) following port placement. Methods A total of 396 female breast cancer patients underwent internal jugular vein chest port placement between 2007 and 2013 and received echo studies every third month...
January 1, 2018: Phlebology
https://www.readbyqxmd.com/read/29768369/pembrolizumab-induced-acute-thrombosis-a-case-report
#4
Kei Kunimasa, Kazumi Nishino, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Toru Kumagai, Fumio Imamura
RATIONALE: Acute thrombosis has not been reported in the literature so far in lung cancer patients as an immune-related adverse event (irAE) associated with PD-1 pathway inhibitors. PATIENTS CONCERNS: Here, we for the first time present two NSCLC (non-small cell lung cancer) patients suffering from acute thrombosis as a pembrolizumab-induced irAE. Immediate treatment with continuous heparin infusion improved their symptoms and enabled them to continue pembrolizumab administration...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29765530/mean-platelet-volume-as-a-predictive-marker-for-venous-thromboembolism-in-patients-treated-for-hodgkin-lymphoma
#5
Joanna Rupa-Matysek, Lidia Gil, Marta Barańska, Dominik Dytfeld, Mieczysław Komarnicki
Mean platelet volume (MPV) is reported to be associated with the risk of venous thromboembolism (VTE) and mortality in patients with cancer. We sought to determine the association of MPV with symptomatic VTE occurrence in patients treated for newly diagnosed Hodgkin lymphoma (HL) and their outcomes. We retrospectively studied 167 consecutive adult patients treated with HL. During first-line treatment 12 (7.2%) patients developed VTE and 14 (8%) died within the observation period. The pre-chemotherapy values of MPV were significantly lower in VTE patients than those without (p=0...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29752323/effectiveness-and-safety-of-rivaroxaban-in-patients-with-cancer-associated-venous-thrombosis
#6
Christine G Kohn, Gary H Lyman, Jan Beyer-Westendorf, Alex C Spyropoulos, Thomas J Bunz, William L Baker, Daniel Eriksson, Anna-Katharina Meinecke, Craig I Coleman
Background: Although not designated as guideline-recommended first-line anticoagulation therapy, patients are receiving rivaroxaban for the treatment and secondary prevention of cancer-associated venous thrombosis (CAT). We sought to estimate the cumulative incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality/hospice care in patients with CAT treated with outpatient rivaroxaban in routine practice. Methods: Using US MarketScan claims data from January 2012 through June 2015, we identified adults with active cancer (using SEER program coding) who had ≥1 primary hospitalization or emergency department discharge diagnosis code for VTE (index event) and received rivaroxaban as their first outpatient anticoagulant within 30 days of the index VTE...
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29746227/comparison-of-an-oral-factor-xa-inhibitor-with-low-molecular-weight-heparin-in-patients-with-cancer-with-venous-thromboembolism-results-of-a-randomized-trial-select-d
#7
Annie M Young, Andrea Marshall, Jenny Thirlwall, Oliver Chapman, Anand Lokare, Catherine Hill, Danielle Hale, Janet A Dunn, Gary H Lyman, Charles Hutchinson, Peter MacCallum, Ajay Kakkar, F D Richard Hobbs, Stavros Petrou, Jeremy Dale, Christopher J Poole, Anthony Maraveyas, Mark Levine
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer. Patient and Methods In this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited...
May 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29738615/apoptotic-vesicles-deathly-players-in-cancer-associated-coagulation
#8
M-R Muhsin-Sharafaldine, A D McLellan
Although cancer is associated with coagulation disorders, it is still unclear how the combination of tumour cell and host factors enhance the hypercoagulable state of cancer patients. Emerging evidence points to a central role for tumour endosomal and plasma-membrane derived vesicular components in the pathogenesis of cancer-related thrombosis. In particular, tumour cell membranes and extracellular vesicles (EV) harbour lipids and proteinaceous coagulation factors able to initiate multiple points within the coagulation matrix...
May 8, 2018: Immunology and Cell Biology
https://www.readbyqxmd.com/read/29737593/management-of-cancer-associated-thrombosis-in-patients-with-thrombocytopenia-guidance-from-the-ssc-of-the-isth
#9
B T Samuelson Bannow, A Lee, A A Khorana, J I Zwicker, S Noble, C Ay, M Carrier
No abstract text is available yet for this article.
April 2, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29714636/extracellular-vesicles-released-in-response-to-respiratory-exposures-implications-for-chronic-disease
#10
Birke J Benedikter, Emiel F M Wouters, Paul H M Savelkoul, Gernot G U Rohde, Frank R M Stassen
Extracellular vesicles (EV) are secreted signaling entities that enhance various pathological processes when released in response to cellular stresses. Respiratory exposures such as cigarette smoke and air pollution exert cellular stresses and are associated with an increased risk of several chronic diseases. The aim of this review was to examine the evidence that modifications in EV contribute to respiratory exposure-associated diseases. Publications were searched using PubMed and Google Scholar with the search terms (cigarette smoke OR tobacco smoke OR air pollution OR particulate matter) AND (extracellular vesicles OR exosomes OR microvesicles OR microparticles OR ectosomes)...
May 1, 2018: Journal of Toxicology and Environmental Health. Part B, Critical Reviews
https://www.readbyqxmd.com/read/29704767/management-of-cancer-associated-upper-extremity-deep-vein-thrombosis-with-and-without-venous-catheters-at-a-tertiary-care-center
#11
Said Y ALKindi, Chatree Chai-Adisaksopha, Matthew Cheah, Lori-Ann Linkins
INTRODUCTION: Data on management of upper extremity deep vein thrombosis (UEDVT) in patients with cancer is limited. The objective of this study was to determine risk factors for UEDVT and the rates of recurrence and bleeding in a real-world setting. METHODS: Retrospective review of consecutive patients assessed for cancer-associated UEDVT. Outcome measures were recurrent venous thromboembolism (VTE), and major and clinically relevant non-major bleeding (CRNMB)...
April 3, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703600/vascular-toxicities-with-vegf-inhibitor-therapies-focus-on-hypertension-and-arterial-thrombotic-events
#12
REVIEW
Rhian M Touyz, Sandra M S Herrmann, Joerg Herrmann
The vascular endothelial growth factor (VEGF) signaling pathway (VSP) fulfills a cardinal role in endothelial cells and its inhibition has profound cardiovascular impact. This is true not only for the normal vasculature but also for the tumor vasculature when VSP inhibitors are used as anti-angiogenic therapies. Generalized endothelial dysfunction predisposes to vasoconstriction, atherosclerosis, platelet activation, and thrombosis (arterial more than venous). All of these have been reported with VSP inhibitors and collectively give rise to vascular toxicities, the most concerning of which are arterial thromboembolic events (ATE)...
March 21, 2018: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/29703491/thrombosis-in-pediatric-patients-with-leukemia
#13
Sarina Levy-Mendelovich, Assaf Arie Barg, Gili Kenet
Acute lymphoblastic leukemia (ALL) is the most common type of cancer diagnosed in children. It is reportedly the most common malignancy associated with thromboembolism in the pediatric age group. Over the last 2 decades, venous thromboembolism (VTE) has been increasingly diagnosed among pediatric ALL patients with an estimated incidence ranging from about 5% (for symptomatic cases) to about 30-70% (following sequential imaging studies in asymptomatic children). The etiology is multifactorial and may stem from alterations of the hemostatic system following various chemotherapy protocols (including use of l-Asparaginase), the presence of central venous lines (CVL), as well as comorbidities, e...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703487/revisiting-occult-cancer-screening-in-patients-with-unprovoked-venous-thromboembolism
#14
Philippe Robin, Marc Carrier
Unprovoked venous thromboembolism (VTE) can be the first manifestation of an unknown cancer. A recently published individual patient data meta-analysis (IPDMA) reported a prevalence of occult cancer detection of 5.2% (95% CI, 4.1% to 6.5%) over a one-year follow-up period, approximately 50% lower than the previously reported 12-month period prevalence. Although an extensive screening strategy was associated with a 2-fold higher probability of cancer detection at initial screening in the IPDMA, not enough evidence exists yet to support the routine use of these tests in patients with unprovoked VTE...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703484/effects-of-platelets-on-cancer-progression
#15
Léa Plantureux, Lydie Crescence, Françoise Dignat-George, Laurence Panicot-Dubois, Christophe Dubois
Platelets are small (2-4 μm), anucleate, hematopoietic cells released by bone marrow megakaryocytes in the bloodstream. For a long time, platelets were described as the major effectors of hemostasis and thrombosis. In 1865, Armand Trousseau demonstrated a close relation between thrombosis and cancer. Subsequently, much clinical and experimental evidence supports the idea that platelets play several roles in the progression of malignancies and in cancer-associated thrombosis. In this review, we will discuss the roles of tumor-educated platelets (TEPs) in the progression of cancer from primary tumors to secondary metastatic outbreaks...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703483/the-role-of-podoplanin-in-cancer-associated-thrombosis
#16
Pegah Mir Seyed Nazari, Julia Riedl, Ingrid Pabinger, Cihan Ay
Venous thromboembolism (VTE) is a frequent and life-threatening complication in patients with cancer. The underlying mechanisms of cancer-associated VTE are still not completely understood. However, emerging studies indicate that the mechanisms differ across tumor types. A recent study revealed that in patients with brain tumors, podoplanin overexpression is strongly correlated with intratumoral thrombotic vessels, hypercoagulability and increased VTE risk. In vitro experiments demonstrated that platelet aggregation induced by human glioblastoma cells was highly podoplanin-dependent...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703480/arterial-thrombosis-and-cancer
#17
Doron Aronson, Benjamin Brenner
Cancer-associated arterial thrombotic events (ATEs) are increasingly recognized in specific malignancies and in association with the expanding armamentarium of novel chemotherapeutic agents. The improved cancer survival led to cardiovascular complications becoming clinically relevant many years after cancer diagnosis. The pathobiology of ATEs in cancer is complex and the individual patient risk for an ATE entails a multifactorial interaction between the traditional cardiovascular risk factors and comorbidities, the specific malignancy and selected therapy...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703478/management-of-recurrent-venous-thromboembolism-in-patients-with-cancer-a-review
#18
Siavash Piran, Sam Schulman
Venous thromboembolism (VTE) occurs in 10-20%% of patients with cancer and is associated with significant mortality and morbidity in these patients. The current standard of care recommended by international guidelines is to use low-molecular-weight heparin (LMWH) for 6months for the management of cancer-associated thrombosis (CAT), which is based on evidence from randomized controlled trials demonstrating that LMWH significantly reduced the risk of recurrent VTE compared with vitamin K antagonists. However, patients with CAT have a high risk of VTE recurrence of up to 20% despite receiving anticoagulation...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703474/platelets-nets-and-cancer
#19
Jessica Cedervall, Anahita Hamidi, Anna-Karin Olsson
In addition to the central role of platelets in hemostasis, they contribute to pathological conditions such as inflammation and tumor progression. Aberrant expression and/or exposure of pro-coagulant factors in the tumor microenvironment induce platelet activation and subsequent release of growth factors from platelet granules. Cancer patients are commonly affected by thrombotic events, as a result of tumor-induced platelet activation. A novel player potentially contributing to cancer-associated thrombosis is the formation of neutrophil extracellular traps (NETs)...
April 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29703471/the-intersection-of-protein-disulfide-isomerase-and-cancer-associated-thrombosis
#20
Jack D Stopa, Jeffrey I Zwicker
The mechanisms underlying the hypercoagulability of cancer are complex and include the upregulation coagulation factors or procoagulant proteins, shedding of microparticles, and direct activation of vascular cells. Protein disulfide isomerase (PDI) is a thiol isomerase secreted from activated platelets and endothelial cells and plays a critical role in both platelet aggregation and fibrin generation. A number of potential intravascular targets of PDI have been identified including cell surface receptors (e...
April 2018: Thrombosis Research
keyword
keyword
120640
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"